Skip to content
Research use only — not for human consumptionBatch documentation on requestThird-party tested purityDiscreet EU delivery21+ onlyMade in EuropeResearch use only — not for human consumptionBatch documentation on requestThird-party tested purityDiscreet EU delivery21+ onlyMade in Europe

RUO · 21+ Tik tyrimų naudojimui (RUO). Visi šioje svetainėje parduodami produktai skirti išimtinai laboratoriniams tyrimams. Jie nėra vaistai, maisto papildai ar preparatai, skirti vartoti žmonėms ar gyvūnams, ir nėra skirti diagnozuoti, gydyti ar užkirsti kelio jokioms ligoms. Naudodamiesi svetaine patvirtinate, kad jums 21+, ir kad perkate tik teisėtiems laboratoriniams tyrimams. Visa tyrimų naudojimo taisyklė

norecipe
CJC-1295 No DAC (5mg) + Ipamorelin (10mg) | Peptide PenResearch use only

CJC-1295 No DAC (5mg) + Ipamorelin (10mg) | Peptide Pen

CJC-1295 (No DAC) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH 1-29), designed to stimulate the pituitary’s natural growth hormone secretion through transient receptor activation. The “No DAC” means this version does not contain the Drug Affinity Complex modification.

Without DAC: CJC-1295 (No DAC), also known as Mod GRF 1-29, has a short half-life (≈30 minutes) and produces pulsatile, physiological GH release.

With DAC: The DAC modification forms a covalent bond to serum albumin, creating a long-acting analogue with a half-life of ≈6–8 days, used in research on sustained GH exposure.

210,00 €incl. VAT
In stockRUO
1

Discreet EU shipping. Certificate of analysis available on request. Not for human or animal consumption.

Sandėliavimas
Store at 2–8 °C. Do not freeze. Shipped with ice packs.
Forma
Užpildyta rankenėlė

CJC-1295 (No DAC) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH 1-29), designed to stimulate the pituitary’s natural growth hormone secretion through transient receptor activation. The “No DAC” means this version does not contain the Drug Affinity Complex modification. Without DAC: CJC-1295 (No DAC), also known as Mod GRF 1-29, has a short half-life (≈30 minutes) and produces pulsatile, physiological GH release. With DAC: The DAC modification forms a covalent bond to serum albumin, creating a long-acting analogue with a half-life of ≈6–8 days, used in research on sustained GH exposure. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that acts synergistically with GHRH analogues. When combined, CJC-1295 (No DAC) and Ipamorelin are studied for their complementary stimulation of the GH axis through independent receptor pathways. Fields of Study Growth hormone secretion studies Metabolic and endocrine regulation Muscle growth and repair Energy and recovery research

Fields of study

  • Growth hormone secretion studies
  • Metabolic and endocrine regulation
  • Muscle growth and repair
  • Energy and recovery research

Susiję junginiai

Rodyti visus